Conference on Tax Risk Mitigation: 2025 Status
Dmitry Kirillov, Partner, Head of Tax and Customs practice at Lidings, will moderate the discussion session "Disputes with Tax Authorities or Defense in Tax Disputes".
Dmitry Kirillov, Partner, Head of Tax and Customs practice at Lidings, will moderate the discussion session "Disputes with Tax Authorities or Defense in Tax Disputes".
Currently, the efforts of state authorities in the fields of pharmaceuticals and healthcare are also aimed at implementing the Strategy for the Development of the Pharmaceutical Industry of the Russian Federation for the Period up to 2030 (hereinafter referred to as the “Pharma 2030 Strategy”). One of the goals of the Pharma 2030 Strategy is to increase the share of domestically produced medicinal products in the total consumption volume from 61.8% to 66.6% by 2030. In this regard, measures to support Russian medicinal products manufacturers continue to be implemented.
On August 7, 2025, a draft law “On Amending the Federal Law ‘On Protection of Competition’” (hereinafter, the “Draft Law”) was published. Prepared by the Federal Antimonopoly Service (hereinafter, the “FAS”), it aims to significantly narrow the scope of antitrust immunities concerning the results of intellectual activity.
On 1 September 2025, a draft resolution of the Government of the Russian Federation “On approving the procedure and criteria for compiling a list of strategically significant medicines” (“Draft Resolution”) was submitted for public discussion.
Alina Smakova, Lidings associate specializing in personal data protection issues, will speak on the topic "Cross-Border Transfer of Personal Data: Building Bridges, Not Walls. Organizing Legal Cross-Border Data Flows".
Large-scale study “The Russian Far East: Industry, Public-Private Partnerships, and Government Support Measures” prepared specifically for the Eastern Economic Forum 2025.
The forum "Localization in Manufacturing" will take place on September 18-19. The event is dedicated to the localization challenges faced by all Russian goods manufacturers since January 1, 2025, following the enactment of Government Decree No. 1875.
Lidings is pleased to invite you and your colleagues to a seminar on launching new drugs in the Russian market.
Regulatory incentives and objective economic realities are driving pharmaceutical companies to seek opportunities for launching new drugs. Such projects are now being conceived and implemented not only by innovative companies but also by players who have traditionally specialized in generics and biosimilars.
During our seminar, we will share our experience and propose effective, cost-efficient legal solutions to help businesses safely and promptly execute new launches at any stage.
Effective September 1, 2025, amendments to Article 135 of the Russian Labor Code will come into force: employers will no longer be able to reduce an employee’s bonus by more than 20% of their monthly salary as a result of a disciplinary action.
We have prepared an overview that explores this topic in greater detail: it covers the concept of bonuses, their types, and how they can be formalized in company policies. We hope this material will be useful in your work and help you assess whether updates to internal documents are needed in advance.
The site uses cookie technology to ensure optimal performance, analyze usage and improve user experience. By continuing to use the site, you consent to the placement of cookies on your device on the terms set out in the Privacy Policy.
To ensure optimal performance, analyze usage and improve user experience, the website may use web analytics systems (including Yandex.Metrica), which may place cookies on your device.
By continuing to use the website, you agree to the use of these technologies and the placement of cookies. You can delete cookies from your device through your browser settings and you can block the placement of cookies, however, in doing so, some website features may not be available due to the engine's technological limitations.
You can find more information in the Privacy Policy.